Kilitch Drugs (India) (KILITCH) Share Price Falls 8.18%: What Today’s Move Shows
- October 21, 2026
- Posted by: Kunal Singla
- Category: News
Kilitch Drugs (India) Share Price was at Rs 202.6, down 8.18% from the previous close, with the company valued at Rs 771.43 crore. The latest KILITCH move places Kilitch Drugs (India) Share Price firmly in focus for investors tracking healthcare names, especially because the day’s decline was visible from the opening bell and persisted through the range. According to Univest data, the price event is confirmed, but no company-specific catalyst is established. That makes Kilitch Drugs (India) Share Price a stock to watch for its price action, its Micro Cap context and its valuation profile rather than for any verified trigger. The current move also matters because it arrives with the broader questions around healthcare stock news, peer comparison and fundamental analysis still open for interpretation.
Kilitch Drugs (India) (KILITCH) Share Price Today: Price Action Analysis
| Metric | Value |
|---|---|
| Current Price | Rs 202.6 |
| Previous Close | Rs 220.65 |
| Today's Move | -Rs 18.05 (-8.18%) |
| Open | Rs 205.65 |
| High | Rs 219.95 |
| Low | Rs 201.3 |
| Market Capitalisation | Rs 771.43 crore |
| Market Cap Category | Micro Cap |
Kilitch Drugs (India) Share Price today moved from an opening level of Rs 205.65 to a high of Rs 219.95 before touching a low of Rs 201.3. The stock last traded at Rs 202.6, which is below the previous close of Rs 220.65 and represents a decline of Rs 18.05, or 8.18%. With market capitalisation at Rs 771.43 crore, Kilitch Drugs (India) Share Price sits in the Micro Cap category and therefore tends to draw attention whenever the price swings sharply. The intraday range shows that the stock recovered part of the early weakness after opening lower, but it still remained beneath the prior close at the latest reading. For readers following Kilitch Drugs (India) Share Price Today, the key fact is simple: price action has turned lower, and the market is still digesting the move as of 21 October 2026 at 12:22:53 PM IST. That sets up the fundamental analysis that follows.
Kilitch Drugs (India) (KILITCH) Fundamental Analysis
| Metric | Value |
|---|---|
| Market Capitalisation | Rs 771.43 crore |
| P/E Ratio | 25.67x |
| P/B Ratio | 2.74x |
| ROE | 12.26% |
| ROCE | 14.5% |
| EPS | Rs 8.6 |
| Book Value Per Share | Rs 80.45 |
| Dividend Yield | 0% |
Kilitch Drugs (India) (KILITCH) fundamental metrics show P/E 25.67x, P/B 2.74x, ROE 12.26%, ROCE 14.5%. These figures provide context only and are not a buy or sell signal.
Kilitch Drugs (India) has a market capitalisation of Rs 771.43 crore and falls in the Micro Cap category, which gives readers a sense of company size before judging valuation. On valuation, P/E at 25.67x, P/B at 2.74x should be read against the sector and peer benchmarks rather than as a standalone signal. Profitability is represented by ROE of 12.26% and ROCE of 14.5%, helping investors compare shareholder returns and capital efficiency. According to latest Univest data, additional metrics include EPS of Rs 8.6, book value per share of Rs 80.45, dividend yield of 0%, adding context to earnings, balance-sheet value and historical payout. Against the latest Univest same industry benchmark, these figures can be compared with benchmark median P/E of 31.73x, median ROE of 11.33%, median ROCE of 13.25%. Taken together, they outline the fundamentals rather than a view on the stock.
Sector and Industry Context
| Metric | Value |
|---|---|
| Sector | Healthcare |
| Industry | Pharmaceuticals & Drugs |
| Benchmark Scope | same industry |
| Company P/E Ratio | 25.67x |
| Benchmark Median P/E | 31.73x |
| Benchmark Average P/E | 45.98x |
| Benchmark P/E Range | 3.1x to 616.89x |
| Company P/B Ratio | 2.74x |
| Benchmark Median P/B | 2.76x |
| Benchmark Average P/B | 4.11x |
| Company ROE | 12.26% |
| Benchmark Median ROE | 11.33% |
| Benchmark Average ROE | 10.14% |
| Company ROCE | 14.5% |
| Benchmark Median ROCE | 13.25% |
| Benchmark Average ROCE | 13.05% |
| Company Market Capitalisation | Rs 771.43 crore |
| Benchmark Median Market Cap | Rs 771.43 crore |
| Benchmark Average Market Cap | Rs 13,467.03 crore |
Kilitch Drugs (India) (KILITCH) operates in the Healthcare sector, within the Pharmaceuticals & Drugs industry.
Kilitch Drugs (India) (KILITCH) has a P/E ratio of 25.67x, which is below the benchmark median of 31.73x, a difference of -19.1%. On its own, the P/E gap is a valuation reference point, not a trading call.
Kilitch Drugs (India) (KILITCH) has a ROE of 12.26%, which is above the benchmark median of 11.33%, a difference of +8.21%. Kilitch Drugs (India) (KILITCH) has a ROCE of 14.5%, which is above the benchmark median of 13.25%, a difference of +9.43%.
Track stocks among today's decliners through the Univest top decliners screener. The peer table below provides the company-level comparison.
Peer Comparison
| Company | Symbol | Market Cap (Cr) | P/E | P/B | ROE (%) | ROCE (%) |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries | SUNPHARMA | 4,18,683.95 | 34.61 | 4.84 | 14.85 | 19.11 |
| Divi's Laboratories | DIVISLAB | 2,41,310.94 | 82.5 | 13.66 | 16.19 | 21.51 |
| Torrent Pharmaceuticals | TORNTPHARM | 1,73,078.79 | 79.36 | 19.28 | 26.76 | 19.27 |
| Laurus Labs | LAURUSLABS | 1,11,433.99 | 101.92 | 19.76 | 18.31 | 18.2 |
| Zydus Lifesciences | ZYDUSLIFE | 1,11,022.18 | 24.6 | 4.12 | 19.69 | 21.39 |
Kilitch Drugs (India) (KILITCH) has a P/E ratio of 25.67x compared with the displayed peer median of 79.36x. This peer read is a relative benchmark rather than a trading signal. Its ROE of 12.26% compares with a peer median of 18.31% across the companies shown in the table. ROCE stood at 14.5% versus the displayed peer median of 19.27%, providing a capital-efficiency comparison. Kilitch Drugs (India) (KILITCH) has a market capitalisation of Rs 771.43 crore. All 5 peers shown have a larger market capitalisation.
Why Investors Are Watching Kilitch Drugs (India)
- Kilitch Drugs (India) Share Price fell 8.18% and stayed below the previous close through the latest reading.
- The stock’s Micro Cap status means Kilitch Drugs (India) Share Price can draw attention on relatively sharp daily moves.
- Its P/E of 25.67 is below the industry median, which adds valuation context to Kilitch Drugs (India) Share Price.
- ROE of 12.26% and ROCE of 14.5% show measurable operating returns behind Kilitch Drugs (India) Share Price.
- Peer comparison places Kilitch Drugs (India) Share Price below several large healthcare names on market cap and above some on valuation efficiency.
About Kilitch Drugs (India)
Kilitch Drugs (India) operates in the Healthcare sector and the Pharmaceuticals & Drugs industry. The company is part of a market segment where valuation, returns and company size can differ sharply from one listed name to another. Based on the available financial context, Kilitch Drugs (India) Share Price reflects a business that is being read through earnings, book value and return ratios rather than through dividend support. For readers following Kilitch Drugs (India) Share Price, the main business context is its position as a smaller listed pharma company within a competitive industry framework.
Track Kilitch Drugs (India) Share Price on Univest
Use Kilitch Drugs (India) (KILITCH) live share-price page, Univest top decliners screener, Univest market blogs to review live stock data, top decliners and related market analysis.
You can track Kilitch Drugs (India) Share Price on Univest for live share price movement, key valuation ratios, 52-week levels and market insights in one place. Univest also helps readers compare Kilitch Drugs (India) Share Price with sector peers, review financial ratios and follow important stock news as it develops during the trading day.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Uniresearch Global Pvt. Ltd. (Research Analyst, SEBI Reg. No. INH000013776, a subsidiary of Univest Communication Technologies Private Limited).
Frequently Asked Questions
Why did Kilitch Drugs (India) Share Price fall today?
Ans. Kilitch Drugs (India) Share Price fell 8.18% to Rs 202.6 from Rs 220.65. According to Univest data, the price event is confirmed, but no company-specific catalyst is established for the move.
What is Kilitch Drugs (India) Share Price today?
Ans. Kilitch Drugs (India) Share Price was last traded at Rs 202.6. The stock opened at Rs 205.65 and moved between Rs 201.3 and Rs 219.95 during the latest reading. The previous close was Rs 220.65.
How much did Kilitch Drugs (India) Share Price decline?
Ans. Kilitch Drugs (India) Share Price declined by Rs 18.05, or 8.18%, from the previous close. That makes it one of the sharper daily moves in the current session for the stock.
What is the market capitalisation of Kilitch Drugs (India)?
Ans. Kilitch Drugs (India) Share Price corresponds to a market capitalisation of Rs 771.43 crore. That places the company in the Micro Cap category and well below the average industry market cap.
What does Kilitch Drugs (India) fundamental analysis show?
Ans. Kilitch Drugs (India) Share Price sits on a P/E of 25.67, P/B of 2.74, ROE of 12.26% and ROCE of 14.5%. EPS is Rs 8.6 and book value is Rs 80.45.
Is Kilitch Drugs (India) Share Price expensive versus peers?
Ans. Kilitch Drugs (India) Share Price is not the highest-valued name in the peer set. Its P/E of 25.67 is below many listed pharma peers and close to Zydus Lifesciences at 24.6.
How does Kilitch Drugs (India) compare with the healthcare sector benchmark?
Ans. Kilitch Drugs (India) Share Price has a P/E below the industry median of 31.73 and a P/B almost exactly at the median of 2.76. Its ROE and ROCE are also above benchmark medians.
Should investors track Kilitch Drugs (India) Share Price on Univest?
Ans. Yes, Kilitch Drugs (India) Share Price is worth tracking on Univest because the platform brings together live price movement, valuation ratios, sector context and peer comparison in one place. The previous close was Rs 220.65.
